Date: 2015-09-08
Type of information: Opening of new premises
Compound: European and Benelux office in Brussels
Company: Sobi - Swedish Orphan Biovitrum (Sweden)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On September 8, 2015, Sobi (Swedish Orphan Biovitrum) formally opened its new European and Benelux office in Brussels, Belgium. The Brussels office will act as an operational hub for Sobi's business and is consistent with the strategic importance of Europe for Sobi, representing approximately 60 per cent of the company's global annual product sales. The office will also enable additional focus on the business in the Benelux region.
The opening of the new office in Brussels is a next step in Sobi's mission to develop and deliver innovative therapies and services to improve the lives of patients living with rare diseases. With more than 600 employees and offices in 24 different countries, Sobi currently delivers therapies to patients in 67 countries across the globe. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases, and two of the company's Haemophilia treatments in development are currently being reviewed by the European Medicines Agency.
Financial terms:
Latest news:
Is general: Yes
